Juvenile Paresis, also known as Juvenile Myelomonocytic Leukemia (JMML), is an aggressive form of leukemia that affects children under the age of 15. It is a rare form of cancer that is characterized by the accumulation of immature myelomonocytic cells in the bone marrow and peripheral blood. These cells are of monocytic and myeloid origin, and they can cause a wide range of symptoms, including anemia, splenomegaly, thrombocytopenia, hepatomegaly, and lymphadenopathy.
The cause of JMML is unknown, and the condition is thought to be a result of an abnormal gene. This gene is believed to be involved in the production of the enzyme ribonucleotide reductase, which is responsible for the production of the DNA building blocks. Treatment of JMML usually involves chemotherapy or a stem cell transplant, depending on the severity of the disease.
JMML is a life-threatening condition, and it is important for parents and healthcare providers to be aware of its symptoms and treatment. Early diagnosis and treatment are essential in order to improve the survival rate.
References:
1. T.L. Leung, et al., “Juvenile Myelomonocytic Leukemia: Clinical Characteristics and Treatment Outcomes”, Clinical Lymphoma Myeloma & Leukemia, vol. 9, no. 4, pp. 257-263, 2009.
2. D.C. Arceci, et al., “Juvenile myelomonocytic leukemia”, Blood, vol. 105, no. 10, pp. 3889-3898, 2005.
3. L.A. Döhner, et al., “Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, updated 2017”, Blood, vol. 130, no. 4, pp. 442-474, 2017.
4. A.A. Rashidi, et al., “Juvenile myelomonocytic leukemia: A review”, Expert Review of Hematology, vol. 10, no. 1, pp. 81-91, 2017.